secwatch.observer — SEC 8-K summary
======================================

Issuer:     4D Molecular Therapeutics, Inc. (FDMT)
CIK:        0001650648
Form:       8-K
Filed at:   2022-06-21T23:59:59+00:00
Accession:  0001193125-22-176718
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

4D Molecular Therapeutics amends bylaws for universal proxy rules and exclusive federal forum for Securities Act claims
--------------------------------------------------------------------------------

- Board amended bylaws on June 14, 2022 to incorporate universal proxy rules for director nominations.
- Forum selection provision changed to make U.S. federal district courts exclusive for Securities Act claims.
- Amended and restated bylaws filed as Exhibit 3.1 to the 8-K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650648/000119312522176718/0001193125-22-176718-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650648/000119312522176718/d277212d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-176718

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer